Pharmabiz
 

Argenta signs drug discovery pact with Boehringer Ingelheim

Harlow, UKFriday, April 19, 2013, 12:00 Hrs  [IST]

Argenta, a Galapagos NV company that provides drug discovery services from target validation to development candidate nomination, has signed a collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, Argenta will apply its extensive respiratory drug discovery services to an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio.

Commenting on the agreement, Dr John Montana, managing director of Argenta said, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading companies in the development of drugs for respiratory diseases, and it is testament to the strength and depth of Argenta’s integrated drug discovery capabilities and expertise in this therapeutic area. We look forward to a fruitful collaboration leading to the delivery of pre-clinical candidates against the target of interest.”

Argenta is a fully-integrated drug discovery services provider and a trusted partner for many world-leading pharmaceutical and biotechnology companies including AstraZeneca, Genentech, Janssen and Zafgen. Argenta’s contract drug discovery services include chemistry, physical sciences, CADD, biology, structural biology, ADMET/PK and respiratory disease models.

 
[Close]